Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Milestone Pharmaceuticals Inc. (MIST : NSDQ)

• Company Description    Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $1.16 Daily Weekly Monthly 20 Day Moving Average: 1,066,488 shares Shares Outstanding: 124.50 (millions) Market Capitalization: $144.42 (millions) Beta: 0.97 52 Week High: $3.06 52 Week Low: $1.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.45% -7.18% 12 Week -37.97% -39.49% Year To Date -42.57% -46.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1111 DR. FREDERIK-PHILIPS BOULEVARD SUITE 420 - MONTREAL,A8 H4M 2X6 CAN ph: 514-336-0444 fax: - investors@mistrasgroup.com http://www.milestonepharma.com

• General Corporate Information    Officers Joseph Oliveto - Chief Executive Officer and Director Robert Wills - Chairman of the Board Amit Hasija - Chief Financial Officer Seth Fischer - Director Lisa M. Giles - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59935V107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 124.50 Most Recent Split Date: (:1) Beta: 0.97 Market Capitalization: $144.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.85 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.48% vs. Previous Quarter: -25.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -84.13% ROE 06/30/26 - - 03/31/26 - -339.33 12/31/25 - -656.73 ROA 06/30/26 - - 03/31/26 - -61.79 12/31/25 - -81.19 Current Ratio 06/30/26 - - 03/31/26 - 9.18 12/31/25 - 8.01 Quick Ratio 06/30/26 - - 03/31/26 - 9.09 12/31/25 - 7.96 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - -3,933.43 12/31/25 - -4,078.78 Book Value 06/30/26 - - 03/31/26 - 0.30 12/31/25 - 0.39 Inventory Turnover 06/30/26 - - 03/31/26 - 0.02 12/31/25 - 0.00 Debt-to-Equity 06/30/26 - - 03/31/26 - 1.61 12/31/25 - 1.37 Debt-to-Capital 06/30/26 - - 03/31/26 - 61.75 12/31/25 - 57.79

Powered by Zacks Investment Research ©